News
The firm said it is in discussions with the FDA to resubmit its biologics license application seeking approval for Ebvallo.
After establishing dosing and safety in Phase I, researchers will evaluate the drug's anti-tumor activity in patients with PSMA-expressing cancers.
DCx sees potential to build multifunctional ADCs using the same technology Repare used to create its small molecule synthetic lethal therapies.
The firm is studying the combination in the first-line setting for head and neck cancer patients who had a PD-L1 combined positive score of less than 1.
The biotech has nominated MB-111, a drug it's developing as a treatment for elevated triglycerides, as its first clinical development candidate.
Researchers at AACR discussed what's next for the drug class, given the disappointing activity of tiragolumab with Tecentriq ...
Biotech firms are engineering smarter, safer gene delivery systems to enhance the safety and efficacy of genetic medicines.
Cancer patients invariably develop resistance to targeted drugs, so drugmakers develop strategies to combat it before ...
Pfizer Misses Revenue Expectations in Q1, But Invests Operational Savings in Oncology-Heavy Pipeline
The company said it took financial hits from the Inflation Reduction Act's Medicare Part D redesign, which included higher ...
Caring Cross, Wellbeing Foundation Africa Partner to Improve Access to Advanced Therapies in Nigeria
NEW YORK – Caring Cross announced Thursday it is partnering with the Wellbeing Foundation Africa to increase access to CAR-T cell therapies and stem cell gene therapies in Nigeria. Through the ...
The New York-based public benefit corporation is advancing three drug candidates for the extremely rare condition.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results